Table 1.
Estimated target population
| % | Referencia | n | ||
|---|---|---|---|---|
| 1 | Patients with lung cancer in 2020 | [26] | 29,188 | |
| 2 | Patients with NSCLC | 85.0% | [14] | 24,810 |
| 3 | Patients with stage IV NSCLC with sample available | 54.5% | [27] | 13,521 |
| 4 | Patients with stage IV NSCLC non-squamous subtype | 66.9% | [16] | 9046 |
| 5 | Patients with stage IV NSCLC squamous subtype | 33.1% | [16] | 4476 |
| 6 | Patients with stage IV NSCLC squamous subtype, never smokers | 11.9% | [28] | 533 |
| 7 | Candidate for molecular diagnosis (steps 4 + 6) | 9579 | ||
| 8 | Patients finally tested for EGFR (testing rate) | 91.4% | [15] | 8755 |
NSCLC Non-small cell lung cancer, EGFR Epidermal growth factor receptor